Results 51 to 60 of about 2,749,589 (298)

Clinical predictors of drug-resistant epilepsy in children

open access: yes, 2021
Background/aim: In up to 20% of epilepsy patients, seizures may not be controlled despite the use of antiepileptic drugs, either alone or in combination. These individuals are considered to have drug-resistant epilepsy. Drug-resistant epilepsy is usually
YİŞ, ULUÇ   +10 more
core   +1 more source

EXPLORING COGNITIVE IMPAIRMENTS IN DRUG-RESISTANT EPILEPSY: INSIGHTS FROM A COMPARATIVE ANALYSIS

open access: yesJournal of Social Sciences
This article explores the cognitive impairments in individuals with drug-resistant epilepsy compared to those with well-controlled epilepsy. The research involves 102 subjects (62 with drug-resistant epilepsy and 40 with well-controlled epilepsy), and ...
DOTEN, Natalia
doaj   +1 more source

Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy

open access: yes, 2023
This study sought to identify differences in cannabis use and perceptions about cannabis in mitigating seizure-related symptoms in patients with epilepsy, and to evaluate differences in these patterns between drug-resistant versus pharmacoresponsive ...
Marielle Darwin, John Thompson
core   +1 more source

Lacosamide in children with drug‐resistant epilepsy [PDF]

open access: yesJournal of Paediatrics and Child Health, 2018
AimTo assess the effectiveness and tolerability of lacosamide in paediatric clinical practice.MethodsA search of our hospital's pharmacy database yielded all children <16 years old dispensed lacosamide for drug‐resistant epilepsy between January 2011 and June 2016. Medical records were reviewed for clinical and drug details. Continued treatment for ≥
Andrea D Rüegger   +2 more
openaire   +3 more sources

RELN gene-related drug-resistant epilepsy with periventricular nodular heterotopia treated with radiofrequency thermocoagulation: a case report

open access: yesFrontiers in Neurology
An increasing number of gene mutations associated with epilepsy have been identified, some linked to gray matter heterotopia—a common cause of drug-resistant epilepsy.
Zijian Li   +5 more
doaj   +1 more source

Sertraline Treatment Can Mimic Niemann‐Pick Type C Biomarker Profile: A Diagnostic Pitfall

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Oxysterols (cholestane‐3β,5α,6β‐triol and 7‐ketocholesterol) and N‐palmitoyl‐O‐phosphocholineserine (PPCS) are sensitive biomarkers for Niemann‐Pick disease type C (NPC) screening. However, false‐positive results occur, with a biomarker profile suggestive of NPC despite the absence of pathogenic variants in genes involved in NPC or ...
Maria Makrygianni   +19 more
wiley   +1 more source

Evaluation of Risk Factors for Epilepsy in Pediatric Patients with Cerebral Palsy

open access: yesBrain Sciences, 2020
Cerebral palsy (CP) is a set of etiologically diverse symptoms that change with the child’s age. It is one of the most frequent causes of motor disability in children. CP occurs at a frequency of 1.5 to 3.0 per 1000 live-born children.
Małgorzata Sadowska   +2 more
doaj   +1 more source

Screening Routine Clinical Notes for Epilepsy Surgery Candidates Using Large Language Models

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Epilepsy surgery is severely underutilized despite proven efficacy, with substantial under‐referral of eligible patients in routine clinical practice. This study evaluated the potential role of large language models (LLMs) as decision‐support tools for screening unstructured clinical notes to identify epilepsy surgery candidates and ...
Uriel Fennig   +9 more
wiley   +1 more source

EVALUATION OF THE PSYCHOLOGICAL INTERVENTION PROGRAM APPLIED TO PEOPLE WITH DRUG-RESISTANT EPILEPSY [PDF]

open access: yesPsihologie
Drug-resistant epilepsy presents a myriad of psychological challenges, including cognitive decline, emotional and behavioral disturbances, loss of autonomy, stigma, psychosocial dysfunction, and a heightened risk of trauma and premature death, all of ...
DOȚEN Natalia
doaj   +1 more source

Unraveling 4‐Phenylbutyrate's Therapeutic Role in SLC6A1 Disorders: Pharmacochaperoning Over HDAC Inhibition

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Variants in SLC6A1, encoding the GABA transporter 1 (GAT‐1), cause epilepsy, autism spectrum disorder, and developmental delay via loss of GABA uptake, impaired trafficking, and ER retention. We previously found that 4‐Phenylbutyrate (PBA), an FDA‐approved drug, restores GABA uptake and reduces seizures in SLC6A1‐related disorders ...
Melissa B. DeLeeuw   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy